Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Oct 4;12:754743. doi: 10.3389/fphar.2021.754743

The Contribution of Dysfunctional Chloride Channels to Neurovascular Deficiency and Neurodegeneration

David A Gascoigne 1, Alexander Drobyshevsky 2, Daniil P Aksenov 1,3,*
PMCID: PMC8520995  PMID: 34671264

Introduction

The brain is a metabolically demanding organ and its health directly depends on maintaining tissue oxygen that is sufficiently high to prevent hypoxia. Focal increases in oxygen demand, in response to sensory signals, motor output, etc., are supported by transient increases in cerebral blood flow via the hemodynamic response (Aksenov et al., 2016). Traditionally, specific products of glutamatergic and astrocytic pathways (i.e., nitric oxide (NO), arachidonic acid metabolites, calcium (Ca2+) and potassium (K+) ions) have been proposed as mechanistic contributors to the hemodynamic response (Archer et al., 1994; Attwell et al., 2010; Ross, 2012; Nippert et al., 2018). However, these mechanisms may not be sufficient drivers of the hemodynamic response. For example, a recent review (Nippert et al., 2018) concluded that, although NO must be present for vasodilation to occur in the cerebral cortex, it is not the active signaling molecule, arteriole vasodilation can occur in the absence of astrocyte Ca2+ increases, Ca2+ signals are characterized by long latencies occurring after the initiation of vasodilation and K+ siphoning through astrocytes does not always play a major role in neurovascular coupling. Moreover, hemodynamic modulatory pathways can have differing levels of influence across various structures. For instance, studies have shown that NO can be an active signaling molecule in the cerebellum (Akgoren et al., 1996; Yang and Iadecola 1997) and hippocampus (Lourenco et al., 2014).

A possible addition to this conventional approach are chloride channel-dependent mechanisms of neurovascular coupling, which may participate in neurovascular deficiency and neurodegeneration. Prominent pathways which employ such chloride channels are gamma aminobutyric acid (GABA) ergic interneuron pathways, which operate via GABA-gated chloride channels (GABAA receptors) and provide a means of rapid signaling. The role of GABAergic interneurons and GABAA receptors in inhibition of neuronal activity is well-known. Interneurons suppress excessive neuronal activity and spatially limit neuronal responses by instigating the hyperpolarization of the cell membrane which has the added benefit of decreasing local oxygen consumption. Additionally, GABA-gated chloride channels can directly participate in regulating cerebral blood flow. GABAA receptors can be found along arterioles (Vaucher et al., 2000) where interneurons make direct morphological connections (Cauli et al., 2004; Tremblay et al., 2016). These chloride channels on brain vessels are functionally active and are able to facilitate substantial vasodilation in response to stimulation, attributable to the hyperpolarization of arteriolar smooth muscles with their subsequent relaxation. Multiple studies have shown that GABAergic interneurons are essential for the full expression of the hemodynamic response in the presence of chemical or electrical stimulation (Kocharyan et al., 2008), during epileptiform discharges (Saillet et al., 2016) as well as in response to both sensory (Aksenov et al., 2019) and optogenetic stimulation (Anenberg et al., 2015). Arteriolar GABA-gated chloride channels, can therefore play an important role in the hemodynamic response due to their fast and profound effect on vasodilation.

In essence, GABA-gated chloride channels can function to prevent hypoxia by both upregulating oxygen supply and downregulating oxygen consumption. Thus, it is our perspective that if the number of these channels or their main biochemical properties are affected, the combination of decreased inhibition and a weakened hemodynamic response can induce local hypoxia, which will alter the intracellular and extracellular environment with neurodegeneration evident thereafter. In support of this perspective, we will briefly review chloride channel dysfunction and neurodegeneration in different diseases, and then provide our interpretation regarding the role of neurovascular deficiency as a medium between chloride channel dysfunction and neurodegeneration.

Neurodegeneration and Chloride Channel Deficiency

Chloride channel deficiency accompanies many neurodegenerative diseases. For example, in Alzheimer’s disease, which is characterized by progressive neurodegeneration starting in hippocampus and entorhinal cortex, the neurotransmission of GABA and GABAergic terminals have been shown to be significantly disrupted in areas neighboring beta-amyloid plaques (Li et al., 2016). Subsequent analysis has shown abnormal upregulation and downregulation of the α2, β1, γ1, and α1, γ2 subunits of GABAA receptors respectively (Limon et al., 2012). Another example is Parkinson’s disease. This progressive neurodegenerative disorder is strongly associated with neuronal cell loss in the substantia nigra and striatum (Fahn and Sulzer, 2004). Although Parkinson’s disease mostly corresponds with the loss of dopaminergic neurons, GABA and GABAA receptor deficiency has also been shown to play an important role in the early and non-motor symptoms of Parkinson’s disease (Murueta-Goyena et al., 2019). These changes in GABAergic pathways are different from those observed in Huntington’s disease. In Huntington’s disease GABAergic interneurons undergo specific morphological alterations (i.e., reduced somatic areas and dendritic field complexity) which accompanies aggressive neurodegeneration in the striatum (Bano et al., 2011).

The etiologies of Alzheimer’s, Parkinson’s and particularly Huntington’s diseases, are often attributed to genetics, however, some diseases (for example, epilepsy) can be independent of such substantial genetic factors. Distinctly, Drug-Resistant Epilepsy (DRE), which occurs in 40% of people with epilepsy (Engel, 2016), has been shown to cause neurodegeneration, often in the temporal lobe. Evidence has elucidated the association between the increased internalization of GABAA receptors and symptoms in DRE (Goodkin et al., 2005; Naylor et al., 2005; Goodkin et al., 2007).

Even complex psychiatric disorders can present with chloride channel affiliated neurodegeneration. For instance, patients with schizophrenia exhibit progressive bilateral neurodegeneration in the grey matter of the temporal and parietal lobes (Whitford et al., 2006), and can exhibit significant under-expression of the α5 subunit of GABAA receptors, the degree of which is correlated with the symptom severity (Marques et al., 2020). Furthermore, autism spectrum disorder (ASD) has demonstrated similar patterns of neurodegeneration to that of schizophrenia. Individuals with ASD have exhibited reduced grey matter volumes in the mirror neuron system (Hadjikhani et al., 2006; Marques et al., 2020). The severity of grey matter thinning in this area was further correlated with the severity of symptoms experienced by those with ASD. Moreover, genetic studies have identified copy number variations and entire locus duplications of the 15p11-q13 chromosomal region in patients with ASD, which lead to under and dysfunctional expression of the β3, α5, and γ3 subunits of GABAA receptors (Hadjikhani et al., 2006). This indicates the potential of chloride channel deficiency to both precede cases of ASD, and have further downstream consequences of neurodegeneration.

Chloride channel dysfunction and neurodegeneration can also occur as an acquired iatrogenic condition; the most notable example of which is neonatal exposure to anesthesia (Aksenov et al., 2020a). Anesthetics that are classified as GABA agonists and glutamate antagonists (Aksenov et al., 2019), have consistently been shown to produce significant neuroapoptosis that is directly correlated with dosage and duration of the anesthesia delivery (Hadjikhani et al., 2006; Zheng et al., 2015; Liu et al., 2018). Moreover, the severity of apoptosis can create a loss of cortical neurons, of which a significant proportion are GABAergic inhibitory interneurons (Istaphanous et al., 2013), and a further study has shown general anesthesia to directly disturb chloride channels (Cabrera et al., 2020) thereby broadening the known contributory effects of anesthesia on neurodegeneration (Aksenov, 2021). These neurodegenerative and apoptotic processes can alter the delicate excitatory/inhibitory balance of cortical networks (Aksenov et al., 2020a). This imbalance can account for, at least in part, the negative developmental changes (Johnston et al., 2002; Aksenov et al., 2020a; Aksenov et al., 2020b) and impeded GABAergic system development (Young et al., 2012; Nisimov et al., 2018) following neonatal anesthesia. This disproportionate cell death leading to a shift in the excitatory/inhibitory balance requires further research in terms of occurrence of the local chronic hypoxia in later years, and how this shift caused by anesthesia, adapts throughout development.

Discussion

We suggest that, in the absence of normal GABAA receptor functioning, neurovascular deficiency could manifest where a weakened hemodynamic response, in combination with decreased inhibition, would be insufficient to support the present metabolic demand. Although this type of neurovascular deficiency does not result in actual ischemic stroke, it engenders chronic intermittent hypoxia which produces neurodegeneration. This clear sequence of events explains the importance of normal chloride channel functioning for preventing chronic hypoxia. Therefore, dysfunctional chloride channels could be a contributory factor to the neurodegeneration in the aforementioned diseases which are epiphenomenal with chloride channel dysfunction.

Indeed, the dangers of hypoxia on the intracellular and extracellular compositions of brain tissue have been well documented. It is known that insufficient oxygen for basic metabolic processes can lead to cell death (Mariotti et al., 2016). Although the neuronal damage is especially severe in sudden onset hypoxia–ischemia, such as in the case of an ischemic stroke, it can also occur as a result of chronic hypoxia (Dheer et al., 2018; Mahakizadeh et al., 2020). Depending on the severity, hypoxia has been shown to increase the production of reactive oxygen species which can accumulate beyond the protective abilities of anti-oxidative systems, causing oxidative stress (Chen et al., 2018). Oxidative stress has a high propensity to interact with macromolecules within cells (e.g., DNA/RNA oxidation, protein oxidation, nitration of tyrosine residues, and lipid peroxidation), leading to cell debilitation (Moreira et al., 2005). Other consequences of hypoxia include a reduction in intracellular and extracellular pH (Rolett et al., 2000; Yao and Haddad, 2004), phosphocreatine (Rolett et al., 2000), inorganic phosphate (Nioka et al., 1990; Rolett et al., 2000) and a buildup of NADH (Rolett et al., 2000; Shetty et al., 2014). These distinct alterations to the intracellular and extracellular environment significantly impair normal cellular functioning and have been shown to be biochemical indicators of neuroapoptosis. Such hypoxia-related events not only demonstrate the ability of insufficient cerebral blood flow to produce neurodegeneration in the immediate undersupplied tissues, but that it can also harmfully affect neighboring tissues as well.

Brain functioning and its metabolic support is a highly integrated process, and embedded within this complex system are GABAergic interneurons and the hemodynamic response. When neurodegeneration is present, determining if neurovascular deficiency precedes this process and exacerbates the neurodegeneration, or suffers as a direct consequence of an unbalanced excitatory/inhibitory system, remains a challenge. These two possibilities are accompanied by respective hypotheses and can therefore be examined by future studies in a controlled environment. A possibility of how one may address this issue includes in vivo studies providing longitudinal measurement of chloride channel and interneuron deficiencies in association with subsequent hemodynamic function and neurodegeneration.

Further interrogation into chloride channel subunit functioning may provide a bottom-up approach to more accurately describe their role in neurodegeneration. A family of genes have been identified (regions CLC2-7) to transcript chloride channels in the brain (Jentsch et al., 1999). These loci represent specific areas of potential genetic manipulation that could identify the discrete contribution of chloride channels and their subunits in degenerative diseases. In addition, the local modulation of chloride channel expression with a viral vector could be used. This type of methodology has proven effective in animal translational models (Miah et al., 2019). Unfortunately, little work has been done to use viral vectors to modulate chloride channel expression in the brain. However, in reference to GABAA receptors, certain benzodiazepine derivatives have shown to allosterically bind to individual subunits. Namely, TPA023 (Atack et al., 2006), HZ166 (Di Lio et al., 2011) and SL651498 (Griebel et al., 2003) are reported to act as α2 and α3 agonists, while CGS 9865 binds to the β+α− interface (Maldifassi et al., 2016). Genetic and subunit-related research may provide further insights into chloride channel dysfunction and lead to etiologically-specific pharmacological solutions to both protect chloride channels, and prevent neurovascular deficiency, in the previously discussed diseases and conditions.

Author Contributions

DA and DG wrote the manuscript, AD provided input on the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

This work was supported by R01GM112715 (National Institute of General Medical Sciences), R01NS107383 (National Institute of Neurological Disorders and Stroke), R01NS119251 (National Institute of Neurological Disorders and Stroke).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Akgören N., Dalgaard P., Lauritzen M. (1996). Cerebral Blood Flow Increases Evoked by Electrical Stimulation of Rat Cerebellar Cortex: Relation to Excitatory Synaptic Activity and Nitric Oxide Synthesis. Brain Res. 710 (1-2), 204–214. 10.1016/0006-8993(95)01354-7 [DOI] [PubMed] [Google Scholar]
  2. Aksenov D. P., Li L., Miller M. J., Wyrwicz A. M. (2016). Blood Oxygenation Level Dependent Signal and Neuronal Adaptation to Optogenetic and Sensory Stimulation in Somatosensory Cortex in Awake Animals. Eur. J. Neurosci. 44 (9), 2722–2729. 10.1111/ejn.13384 [DOI] [PubMed] [Google Scholar]
  3. Aksenov D. P., Li L., Miller M. J., Wyrwicz A. M. (2019). Role of the Inhibitory System in Shaping the BOLD fMRI Response. Neuroimage 201, 116034. 10.1016/j.neuroimage.2019.116034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aksenov D. P., Miller M. J., Dixon C. J., Drobyshevsky A. (2020a). Impact of Anesthesia Exposure in Early Development on Learning and Sensory Functions. Dev. Psychobiol 62 (5), 559–572. 10.1002/dev.21963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Aksenov D. P., Miller M. J., Dixon C. J., Wyrwicz A. M. (2019). The Effect of Sevoflurane and Isoflurane Anesthesia on Single Unit and Local Field Potentials. Exp. Brain Res. 237 (6), 1521–1529. 10.1007/s00221-019-05528-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Aksenov D. P. (2021). Normal Development of Local Neurovascular Interactions and the Diagnostic Value of Resting State Functional MRI in Neurovascular Deficiency Based on the Example of Neonatal Anesthesia Exposure. Front. Neurol. 12, 664706. 10.3389/fneur.2021.664706 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Aksenov D. P., Venkatasubramanian P. N., Miller M. J., Dixon C. J., Li L., Wyrwicz A. M. (2020b). Effects of Neonatal Isoflurane Anesthesia Exposure on Learning-specific and Sensory Systems in Adults. Sci. Rep. 10 (1), 13832. 10.1038/s41598-020-70818-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Anenberg E., Chan A. W., Xie Y., LeDue J. M., Murphy T. H. (2015). Optogenetic Stimulation of GABA Neurons Can Decrease Local Neuronal Activity while Increasing Cortical Blood Flow. J. Cereb. Blood Flow Metab. 35 (10), 1579–1586. 10.1038/jcbfm.2015.140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Archer S. L., Huang J. M., Hampl V., Nelson D. P., Shultz P. J., Weir E. K. (1994). Nitric Oxide and cGMP Cause Vasorelaxation by Activation of a Charybdotoxin-Sensitive K Channel by cGMP-dependent Protein Kinase. Proc. Natl. Acad. Sci. U S A. 91 (16), 7583–7587. 10.1073/pnas.91.16.7583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Atack J. R., Wafford K. A., Tye S. J., Cook S. M., Sohal B., Pike A., et al. (2006). TPA023 [7-(1,1-Dimethylethyl)-6-(2-Ethyl-2h-1,2,4-Triazol-3-Ylmethoxy)-3-(2-Fluorophenyl)-1,2,4-Triazolo[4,3-B]pyridazine], an Agonist Selective for Alpha2- and Alpha3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates. J. Pharmacol. Exp. Ther. 316 (1), 410–422. 10.1124/jpet.105.089920 [DOI] [PubMed] [Google Scholar]
  11. Attwell D., Buchan A. M., Charpak S., Lauritzen M., Macvicar B. A., Newman E. A. (2010). Glial and Neuronal Control of Brain Blood Flow. Nature 468 (7321), 232–243. 10.1038/nature09613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bano D., Zanetti F., Mende Y., Nicotera P. (2011). Neurodegenerative Processes in Huntington's Disease. Cell Death Dis 2, e228. 10.1038/cddis.2011.112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cabrera O. H., Tesic V., Tat Q. L., Chastain S., Quillinan N., Jevtovic-Todorovic V. (2020). Sevoflurane-Induced Dysregulation of Cation-Chloride Cotransporters NKCC1 and KCC2 in Neonatal Mouse Brain. Mol. Neurobiol. 57 (1), 1–10. 10.1007/s12035-019-01751-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cauli B., Tong X. K., Rancillac A., Serluca N., Lambolez B., Rossier J., et al. (2004). Cortical GABA Interneurons in Neurovascular Coupling: Relays for Subcortical Vasoactive Pathways. J. Neurosci. 24 (41), 8940–8949. 10.1523/JNEUROSCI.3065-04.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chen R., Lai U. H., Zhu L., Singh A., Ahmed M., Forsyth N. R. (2018). Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors. Front Cel Dev Biol 6, 132. 10.3389/fcell.2018.00132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dheer A., Jain V., Kushwah N., Kumar R., Prasad D., Singh S. B. (2018). Temporal and Spatial Changes in Glial Cells during Chronic Hypobaric Hypoxia: Role in Neurodegeneration. Neuroscience 383, 235–246. 10.1016/j.neuroscience.2018.04.026 [DOI] [PubMed] [Google Scholar]
  17. Di Lio A., Benke D., Besson M., Desmeules J., Daali Y., Wang Z. J., et al. (2011). HZ166, a Novel GABAA Receptor Subtype-Selective Benzodiazepine Site Ligand, Is Antihyperalgesic in Mouse Models of Inflammatory and Neuropathic Pain. Neuropharmacology 60 (4), 626–632. 10.1016/j.neuropharm.2010.11.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Engel J., Jr. (2016). What Can We Do for People with Drug-Resistant Epilepsy? the 2016 Wartenberg Lecture. Neurology 87 (23), 2483–2489. 10.1212/WNL.0000000000003407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fahn S., Sulzer D. (2004). Neurodegeneration and Neuroprotection in Parkinson Disease. NeuroRx 1 (1), 139–154. 10.1602/neurorx.1.1.139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goodkin H. P., Sun C., Yeh J. L., Mangan P. S., Kapur J. (2007). GABA(A) Receptor Internalization during Seizures. Epilepsia 48 (Suppl. 5), 109–113. 10.1111/j.1528-1167.2007.01297.x [DOI] [PubMed] [Google Scholar]
  21. Goodkin H. P., Yeh J. L., Kapur J. (2005). Status Epilepticus Increases the Intracellular Accumulation of GABAA Receptors. J. Neurosci. 25 (23), 5511–5520. 10.1523/JNEUROSCI.0900-05.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Depoortere H., et al. (2003). SL651498, a GABAA Receptor Agonist with Subtype-Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. CNS Drug Rev. 9 (1), 3–20. 10.1111/j.1527-3458.2003.tb00241.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hadjikhani N., Joseph R. M., Snyder J., Tager-Flusberg H. (2006). Anatomical Differences in the Mirror Neuron System and Social Cognition Network in Autism. Cereb. Cortex 16 (9), 1276–1282. 10.1093/cercor/bhj069 [DOI] [PubMed] [Google Scholar]
  24. Istaphanous G. K., Ward C. G., Nan X., Hughes E. A., McCann J. C., McAuliffe J. J., et al. (2013). Characterization and Quantification of Isoflurane-Induced Developmental Apoptotic Cell Death in Mouse Cerebral Cortex. Anesth. Analg 116 (4), 845–854. 10.1213/ANE.0b013e318281e988 [DOI] [PubMed] [Google Scholar]
  25. Jentsch T. J., Friedrich T., Schriever A., Yamada H. (1999). The CLC Chloride Channel Family. Pflugers Arch. 437 (6), 783–795. 10.1007/s004240050847 [DOI] [PubMed] [Google Scholar]
  26. Johnston M. V., Nakajima W., Hagberg H. (2002). Mechanisms of Hypoxic Neurodegeneration in the Developing Brain. Neuroscientist 8 (3), 212–220. 10.1177/1073858402008003007 [DOI] [PubMed] [Google Scholar]
  27. Kocharyan A., Fernandes P., Tong X. K., Vaucher E., Hamel E. (2008). Specific Subtypes of Cortical GABA Interneurons Contribute to the Neurovascular Coupling Response to Basal Forebrain Stimulation. J. Cereb. Blood Flow Metab. 28 (2), 221–231. 10.1038/sj.jcbfm.9600558 [DOI] [PubMed] [Google Scholar]
  28. Li Y., Sun H., Chen Z., Xu H., Bu G., Zheng H. (2016). Implications of GABAergic Neurotransmission in Alzheimer's Disease. Front. Aging Neurosci. 8, 31. 10.3389/fnagi.2016.00031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Limon A., Reyes-Ruiz J. M., Miledi R. (2012). Loss of Functional GABA(A) Receptors in the Alzheimer Diseased Brain. Proc. Natl. Acad. Sci. U S A. 109 (25), 10071–10076. 10.1073/pnas.1204606109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Liu Y., Liu C., Zeng M., Han X., Zhang K., Fu Y., et al. (2018). Influence of Sevoflurane Exposure on Mitogen-Activated Protein Kinases and Akt/GSK-3β/CRMP-2 Signaling Pathways in the Developing Rat Brain. Exp. Ther. Med. 15 (2), 2066–2073. 10.3892/etm.2017.5651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lourenço C. F., Santos R. M., Barbosa R. M., Cadenas E., Radi R., Laranjinha J. (2014). Neurovascular Coupling in hippocampus Is Mediated via Diffusion by Neuronal-Derived Nitric Oxide. Free Radic. Biol. Med. 73, 421–429. 10.1016/j.freeradbiomed.2014.05.021 [DOI] [PubMed] [Google Scholar]
  32. Mahakizadeh S., Mokhtari T., Navaee F., Poorhassan M., Tajik A., Hassanzadeh G. (2020). Effects of Chronic Hypoxia on the Expression of seladin-1/Tuj1 and the Number of Dark Neurons of hippocampus. J. Chem. Neuroanat. 104, 101744. 10.1016/j.jchemneu.2020.101744 [DOI] [PubMed] [Google Scholar]
  33. Maldifassi M. C., Baur R., Sigel E. (2016). Molecular Mode of Action of CGS 9895 at α1β2γ2GABAAreceptors. J. Neurochem. 138 (5), 722–730. 10.1111/jnc.13711 [DOI] [PubMed] [Google Scholar]
  34. Mariotti L., Losi G., Sessolo M., Marcon I., Carmignoto G. (2016). The Inhibitory Neurotransmitter GABA Evokes Long-Lasting Ca(2+) Oscillations in Cortical Astrocytes. Glia 64 (3), 363–373. 10.1002/glia.22933 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Marques T. R., Ashok A. H., Angelescu I., Borgan F., Myers J., Lingford-Hughes A., et al. (2020). GABA-A Receptor Differences in Schizophrenia: a Positron Emission Tomography Study Using [(11)C]Ro154513. Mol. Psychiatry. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Miah K. M., Hyde S. C., Gill D. R. (2019). Emerging Gene Therapies for Cystic Fibrosis. Expert Rev. Respir. Med. 13 (8), 709–725. 10.1080/17476348.2019.1634547 [DOI] [PubMed] [Google Scholar]
  37. Moreira P. I., Smith M. A., Zhu X., Nunomura A., Castellani R. J., Perry G. (2005). Oxidative Stress and Neurodegeneration. Ann. N. Y Acad. Sci. 1043, 545–552. 10.1196/annals.1333.062 [DOI] [PubMed] [Google Scholar]
  38. Murueta-Goyena A., Andikoetxea A., Gómez-Esteban J. C., Gabilondo I. (2019). Contribution of the GABAergic System to Non-motor Manifestations in Premotor and Early Stages of Parkinson's Disease. Front. Pharmacol. 10, 1294. 10.3389/fphar.2019.01294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Naylor D. E., Liu H., Wasterlain C. G. (2005). Trafficking of GABA(A) Receptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status Epilepticus. J. Neurosci. 25 (34), 7724–7733. 10.1523/JNEUROSCI.4944-04.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nioka S., Chance B., Smith D. S., Mayevsky A., Reilly M. P., Alter C., et al. (1990). Cerebral Energy Metabolism and Oxygen State during Hypoxia in Neonate and Adult Dogs. Pediatr. Res. 28 (1), 54–62. 10.1203/00006450-199007000-00013 [DOI] [PubMed] [Google Scholar]
  41. Nippert A. R., Biesecker K. R., Newman E. A. (2018). Mechanisms Mediating Functional Hyperemia in the Brain. Neuroscientist 24 (1), 73–83. 10.1177/1073858417703033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Nisimov H., Orenbuch A., Pleasure S. J., Golan H. M. (2018). Impaired Organization of GABAergic Neurons Following Prenatal Hypoxia. Neuroscience 384, 300–313. 10.1016/j.neuroscience.2018.05.021 [DOI] [PubMed] [Google Scholar]
  43. Rolett E. L., Azzawi A., Liu K. J., Yongbi M. N., Swartz H. M., Dunn J. F. (2000). Critical Oxygen Tension in Rat Brain: a Combined (31)P-NMR and EPR Oximetry Study. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279 (1), R9–R16. 10.1152/ajpregu.2000.279.1.R9 [DOI] [PubMed] [Google Scholar]
  44. Ross W. N., Manita S. (2012). Imaging Calcium Waves and sparks in central Neurons. Cold Spring Harb Protoc. 2012 (3), 1087–1091. 10.1101/pdb.prot071480 [DOI] [PubMed] [Google Scholar]
  45. Saillet S., Quilichini P. P., Ghestem A., Giusiano B., Ivanov A. I., Hitziger S., et al. (2016). Interneurons Contribute to the Hemodynamic/metabolic Response to Epileptiform Discharges. J. Neurophysiol. 115 (3), 1157–1169. 10.1152/jn.00994.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Shetty P. K., Galeffi F., Turner D. A. (2014). Nicotinamide Pre-treatment Ameliorates NAD(H) Hyperoxidation and Improves Neuronal Function after Severe Hypoxia. Neurobiol. Dis. 62, 469–478. 10.1016/j.nbd.2013.10.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Tremblay R., Lee S., Rudy B. (2016). GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits. Neuron 91 (2), 260–292. 10.1016/j.neuron.2016.06.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Vaucher E., Tong X. K., Cholet N., Lantin S., Hamel E. (2000). GABA Neurons Provide a Rich Input to Microvessels but Not Nitric Oxide Neurons in the Rat Cerebral Cortex: a Means for Direct Regulation of Local Cerebral Blood Flow. J. Comp. Neurol. 421, 161–171. [DOI] [PubMed] [Google Scholar]
  49. Whitford T. J., Grieve S. M., Farrow T. F., Gomes L., Brennan J., Harris A. W., et al. (2006). Progressive Grey Matter Atrophy over the First 2-3 Years of Illness in First-Episode Schizophrenia: a Tensor-Based Morphometry Study. Neuroimage 32 (2), 511–519. 10.1016/j.neuroimage.2006.03.041 [DOI] [PubMed] [Google Scholar]
  50. Yang G., Iadecola C. (1997). Obligatory Role of NO in Glutamate-dependent Hyperemia Evoked from Cerebellar Parallel Fibers. Am. J. Physiol. 272 (4 Pt 2), R1155–R1161. 10.1152/ajpregu.1997.272.4.R1155 [DOI] [PubMed] [Google Scholar]
  51. Yao H., Haddad G. G. (2004). Calcium and pH Homeostasis in Neurons during Hypoxia and Ischemia. Cell Calcium 36 (3-4), 247–255. 10.1016/j.ceca.2004.02.013 [DOI] [PubMed] [Google Scholar]
  52. Young S. Z., Taylor M. M., Wu S., Ikeda-Matsuo Y., Kubera C., Bordey A. (2012). NKCC1 Knockdown Decreases Neuron Production through GABA(A)-regulated Neural Progenitor Proliferation and Delays Dendrite Development. J. Neurosci. 32 (39), 13630–13638. 10.1523/JNEUROSCI.2864-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zheng S. Q., Chen X., Wang Y. J., An L. X. (2015). [Effects of Sevoflurane on Brain Neuroapoptosis and Ability of Long-Term Learning and Memory in Newborn Rats]. Beijing Da Xue Xue Bao Yi Xue Ban 47 (4), 674–678. [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES